


Ervogastat

Cat. No.:	HY-111620
CAS No.:	2186700-33-2
Molecular Formula:	C ₂₁ H ₂₁ N ₅ O ₄
Molecular Weight:	407.42
Target:	Acyltransferase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (306.81 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.4545 mL	12.2723 mL	24.5447 mL
		5 mM	0.4909 mL	2.4545 mL	4.9089 mL
		10 mM	0.2454 mL	1.2272 mL	2.4545 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.11 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.11 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.11 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Ervogastat (PF-06865571) is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor (DGAT2i). Ervogastat alone reduces steatosis and hepatic triglyceride levels in non-alcoholic steatohepatitis (NASH) ^[1] . Ervogastat combination with Clesacostat (an acetyl CoA-carboxylase inhibitor (ACCi)) can be used for the research of NASH with liver fibrosis therapy ^{[1][2]} .
IC ₅₀ & Target	IC50: DGAT2 ^[1]

REFERENCES

[1]. PFIZER INVESTOR DAY FEATURES SIGNIFICANT NUMBER OF PIPELINE ADVANCES FOR COVID-19 PROGRAMS AND ACROSS NUMEROUS THERAPEUTIC AREAS

[2]. Internal Medicine

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA